Skip to main content

Mecanismos que median el avance de la discapacidad en la esclerosis múltiple. Identificación de nuevos factores pronósticos y dianas terapéuticas.

PI24/01018

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal para Impulsar la Investigación Científico-Técnica y su Transferencia
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de I+D+i en Salud
Call year 2024
State Plan 2021-2023 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION INVESTIGACION BIOMEDICA HOSPITAL RAMON Y CAJAL
Execution centre INSTITUTO RAMON Y CAJAL DE INVESTIGACION SANITARIA (IRYCIS)

Resultados relacionados

Resultados totales (Incluyendo duplicados): 1
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Combining CSF and Serum Biomarkers to Differentiate Mechanisms of Disability Worsening in Multiple Sclerosis

  • Monreal, Enric|||0000-0003-3293-0125
  • Fernández Velasco, José Ignacio|||0000-0001-9148-671X
  • Sainz De La Maza, Susana
  • Espiño, Mercedes
  • Villarrubia, Noelia
  • Roldán, Ernesto
  • Aladro, Yolanda|||0000-0001-9459-5452
  • Cuello, Juan Pablo
  • Ayuso-Peralta, Lucía
  • Rodero-Romero, Alexander
  • Chico-García, Juan Luís
  • Rodríguez-Jorge, Fernando
  • Quiroga-Varela, Ana
  • Rodríguez-Martín, Eulalia
  • Pilo, Belén
  • Martín Ávila, Guillermo
  • Martínez Ginés, María Luisa
  • García Domínguez, José Manuel
  • Rubio, Lluïsa
  • Llufriu, Sara|||0000-0003-4273-9121
  • Comabella López, Manuel|||0000-0002-2373-6657
  • Montalban, Xavier|||0000-0002-0098-9918
  • Álvarez Bravo, Gary|||0000-0003-0342-0177
  • Veiga-Gonzalez, José Luis
  • Masjuan, Jaime|||0000-0003-1329-0943
  • Costa-Frossard, Lucienne|||0000-0002-6512-4413
  • Villar, Luisa M.|||0000-0002-9067-3668
The combined use of serum and CSF biomarkers for prognostic stratification in multiple sclerosis (MS) remains underexplored. This multicenter observational study investigated associations between serum neurofilament light chain (sNfL), glial fibrillary acidic protein (sGFAP), and CSF lipid-specific IgM oligoclonal bands (LS-OCMB) with different forms of disability worsening, such as relapse-associated worsening (RAW), active progression independent of relapse activity (aPIRA), and non-active PIRA (naPIRA). A total of 535 patients with MS were included, all sampled within one year of disease onset. Biomarkers were quantified using single-molecule array and immunoblotting techniques, and CSF cell subsets were analyzed by flow cytometry. High sNfL z-scores and LS-OCMB positivity were independently associated with increased risk of RAW and aPIRA, collectively termed inflammatory-associated worsening (IAW), while elevated sGFAP levels predicted naPIRA. Patients with both high sNfL and LS-OCMB positivity had the highest risk of IAW. Among LS-OCMB-positive patients, higher regulatory T cell percentages were associated with lower sNfL levels, suggesting a protective role. Conversely, in LS-OCMB-negative patients, sNfL levels correlated with CSF C3 concentrations. These findings support the complementary role of sNfL, sGFAP, and LS-OCMB in identifying distinct mechanisms of disease worsening and may inform early personalized management strategies in MS.